Literature DB >> 22411291

Anticoagulation therapy. Dabigatran and risk of myocardial infarction.

John W Eikelboom1, Jeffrey I Weitz.   

Abstract

Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically review the evidence for this association and consider the implications for patient care.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22411291     DOI： 10.1038/nrcardio.2012.34

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

1.  Newly identified events in the RE-LY trial.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; Paul A Reilly; Lars Wallentin
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

Authors:  Stefan H Hohnloser; Jonas Oldgren; Sean Yang; Lars Wallentin; Michael Ezekowitz; Paul Reilly; John Eikelboom; Martina Brueckmann; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2012-01-03       Impact factor: 29.690

3.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Authors:  Jonas Oldgren; Andrzej Budaj; Christopher B Granger; Yasser Khder; Juliet Roberts; Agneta Siegbahn; Jan G P Tijssen; Frans Van de Werf; Lars Wallentin
Journal:  Eur Heart J       Date:  2011-05-07       Impact factor: 29.983

4.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

Review 5.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

Authors:  Ken Uchino; Adrian V Hernandez
Journal:  Arch Intern Med       Date:  2012-01-09

6.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Authors:  John A Cairns; Stuart Connolly; Sean McMurtry; Michael Stephenson; Mario Talajic
Journal:  Can J Cardiol       Date:  2011 Jan-Feb       Impact factor: 5.223

7.  Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.

Authors: 
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

8.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

9.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.

Authors:  Lars Wallentin; Robert G Wilcox; W Douglas Weaver; Håkan Emanuelsson; Andrew Goodvin; Per Nyström; Anders Bylock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321
  9 in total
  10 in total

Review 1.  Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Authors:  Sascha Meyer Dos Santos; Sebastian Harder
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

Review 2.  Evolving use of new oral anticoagulants for treatment of venous thromboembolism.

Authors:  Calvin H Yeh; Peter L Gross; Jeffrey I Weitz
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

3.  Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.

Authors:  Yoon K Loke; Shiva Pradhan; Jessica Ka-Yan Yeong; Chun Shing Kwok
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

4.  Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.

Authors:  Ihsan Gadi; Sameen Fatima; Berend Isermann; Khurrum Shahzad; Ahmed Elwakiel; Sumra Nazir; Moh'd Mohanad Al-Dabet; Rajiv Rana; Fabian Bock; Jayakumar Manoharan; Dheerendra Gupta; Ronald Biemann; Bernhard Nieswandt; Ruediger Braun-Dullaeus; Christian Besler; Markus Scholz; Robert Geffers; John H Griffin; Charles T Esmon; Shrey Kohli
Journal:  Circ Res       Date:  2020-12-23       Impact factor: 17.367

Review 5.  Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jonathan Douxfils; Fanny Buckinx; François Mullier; Valentine Minet; Véronique Rabenda; Jean-Yves Reginster; Philippe Hainaut; Olivier Bruyère; Jean-Michel Dogné
Journal:  J Am Heart Assoc       Date:  2014-06-06       Impact factor: 5.501

6.  Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.

Authors:  E Perzborn; S Heitmeier; U Buetehorn; V Laux
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

7.  Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran.

Authors:  Aleksandra Lenart-Migdalska; Leszek Drabik; Magdalena Kaźnica-Wiatr; Lidia Tomkiewicz-Pająk; Piotr Podolec; Maria Olszowska
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 8.  Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.

Authors:  K Huber; S J Connolly; A Kher; F Christory; G-A Dan; R Hatala; R G Kiss; B Meier; B Merkely; B Pieske; T Potpara; J Stępińska; N Vene Klun; D Vinereanu; P Widimský
Journal:  Int J Clin Pract       Date:  2013-04-05       Impact factor: 2.503

Review 9.  The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.

Authors:  Christopher R Ellis; Daniel W Kaiser
Journal:  Vasc Health Risk Manag       Date:  2013-07-09

10.  In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus.

Authors:  Kathleen E Brummel-Ziedins; Matthew Gissel; Jacqueline Neuhaus; Álvaro H Borges; David R Chadwick; Sean Emery; James D Neaton; Russell P Tracy; Jason V Baker
Journal:  Res Pract Thromb Haemost       Date:  2018-09-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.